Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
No plan disclosedOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 1 of the 13 calendar months from Oct 2025 to Oct 2026: Mar 2026.
- Largest single sale: $1.3M (44,173 shares) of NewAmsterdam Pharma Co N.V. on Mar 11, 2026. Filing
- No sale on record before this period.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | Director | Dec 29, 2023 | Mar 12, 2026 |
| Gilead Sciences (GILD) | Former Former EVP Cardio Therapeutics | Apr 27, 2009 | May 8, 2009 |
Recent filings
The last 4 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Mar 11, 2026, NewAmsterdam Pharma Co N.V.: sold 44,619 shares for $1.4M, no plan disclosed. 1 filing: 1
- Mar 9, 2026, NewAmsterdam Pharma Co N.V.: 44,619 shares acquired by exercising derivatives. 1 filing: 1
- Mar 6, 2026, NewAmsterdam Pharma Co N.V.: sold 28,186 shares for $829K, no plan disclosed (some held indirectly). 1 filing: 1
- Jan 7, 2026, NewAmsterdam Pharma Co N.V.: 3,400 shares granted. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.